Circulating sex hormones and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of bleeding episodes in levonorgestrel-implant users.
Unpredictable endometrial bleeding is the major side-effect of levonorgestrel-releasing s.c. implants (Norplant), otherwise a method of choice for long-term contraception. The mechanisms responsible for bleeding are still unknown and no reliable treatment is available. Several matrix metalloproteinases (MMP) are expressed and activated in human endometrium only at menstruation and specific synthetic inhibitors of MMP fully prevent the tissue breakdown that occurs in menstrual-like endometrial explants. To investigate whether MMP are inappropriately expressed and activated in Norplant-treated endometria during bleeding episodes, volunteers were recruited to provide blood and endometrial biopsies at the start of bleeding episodes and during non-bleeding intervals. Whereas serum concentrations of levonorgestrel and sex hormones showed no change at bleeding, except for a slight decrease of oestradiol concentration, the expression and activation of stromelysin-1 released by explants cultured for 1 day were consistently increased at the start of bleeding episodes. Furthermore, stromelysin-1 was immunolocalized in stromal cells within breakdown areas of several bleeding endometria, but not in non-bleeding endometria. These observations suggest that the expression and activation of stromelysin-1 participate in the initiation of bleeding episodes upon Norplant contraception. New strategies in the prevention and treatment of abnormal bleeding based on MMP control should be envisaged.
Marbaix
E
E
Christian de Duve Institute of Cellular Pathology, Department of Pathology, Medical School of the Université catholique de Louvain, Bruxelles, Belgium. marbaix@cell.ucl.ac.be
Vekemans
M
M
Galant
C
C
Rigot
V
V
Lemoine
P
P
Dubois
D
D
Picquet
C
C
Henriet
P
P
Twagirayezu
P
P
Sufi
S
S
Eeckhout
Y
Y
Courtoy
P J
PJ
D000328:Adult; D001706:Biopsy; D015153:Blotting, Western; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects*; D017077:Culture Media, Conditioned; D046508:Culture Techniques; D004343:Drug Implants; D004717:Endometrium / Q000201:enzymology* / Q000473:pathology; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D012739:Gonadal Steroid Hormones / Q000097:blood*; D006801:Humans; D007150:Immunohistochemistry; D016912:Levonorgestrel / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D019278:Matrix Metalloproteinase 3 / Q000032:analysis / Q000378:metabolism*; D011374:Progesterone / Q000097:blood; D045167:Progesterone Congeners / Q000009:adverse effects; D014592:Uterine Hemorrhage / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology
D003271:Contraceptive Agents, Female; D017077:Culture Media, Conditioned; D004343:Drug Implants; D012739:Gonadal Steroid Hormones; D045167:Progesterone Congeners; D011374:Progesterone; D004958:Estradiol; D016912:Levonorgestrel; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D019278:Matrix Metalloproteinase 3